Literature DB >> 9328161

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study.

J F Tsai1, J E Jeng, M S Ho, W Y Chang, M Y Hsieh, Z Y Lin, J H Tsai.   

Abstract

To assess whether there is an additive effect between chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on the development of hepatocellular carcinoma (HCC), 400 consecutive cirrhotic patients were followed prospectively with periodic abdominal ultrasound examination and measurement of serum alpha-fetoprotein (AFP) level every 4 months. During a follow-up of 1185 person-years, 80 (20%) patients developed HCC, with an annual incidence of 6.8%. The annual incidence was 2.0% in patients negative for hepatitis B surface antigen (HBsAg) and antibodies to HCV (anti-HCV), 6.6% in patients with HBsAg alone, 7.0% in patients with anti-HCV alone and 13.3% in patients co-infected with HBV and HCV. There was a positive linear trend in the annual incidence of HCC among patients without either marker, patients with single viral infection and patients with dual viral infection (P[for trend] < 0.0001). Cox's proportional hazard model indicated that HCV/HBV co-infection [hazard ratio (HR), 6.41; 95% confidence interval (CI), 1.80-22.80], anti-HCV alone (HR, 3.74; 95% CI, 1.07-13.07) and HBsAg alone (HR, 4.06; 95% CI, 1.23-13.34) were independently risk factors of HCC. In conclusion, there is an additive and independent effect modification of HCV and HBV infection on HCC development.

Entities:  

Mesh:

Year:  1997        PMID: 9328161      PMCID: PMC2228256          DOI: 10.1038/bjc.1997.493

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.

Authors:  K Kiyosawa; T Sodeyama; E Tanaka; Y Gibo; K Yoshizawa; Y Nakano; S Furuta; Y Akahane; K Nishioka; R H Purcell
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

2.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

3.  Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma.

Authors:  E Kaklamani; D Trichopoulos; A Tzonou; X Zavitsanos; Y Koumantaki; A Hatzakis; C C Hsieh; S Hatziyannis
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

Review 4.  Natural history of chronic hepatitis B virus infection: new light on an old story.

Authors:  D S Chen
Journal:  J Gastroenterol Hepatol       Date:  1993 Sep-Oct       Impact factor: 4.029

5.  Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan.

Authors:  J E Jeng; J F Tsai
Journal:  J Med Virol       Date:  1991-05       Impact factor: 2.327

6.  Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; L Y Wang; M Y Hsieh; S C Chen; W L Chuang; Z Y Lin; J H Tsai
Journal:  J Med Virol       Date:  1993-12       Impact factor: 2.327

7.  Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area.

Authors:  P Paterlini; F Driss; B Nalpas; E Pisi; D Franco; P Berthelot; C Bréchot
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

8.  Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.

Authors:  R G Simonetti; C Cammà; F Fiorello; M Cottone; M Rapicetta; L Marino; G Fiorentino; A Craxì; A Ciccaglione; R Giuseppetti
Journal:  Ann Intern Med       Date:  1992-01-15       Impact factor: 25.391

9.  Hepatitis B and C virus infection as risk factors for liver cirrhosis and cirrhotic hepatocellular carcinoma: a case-control study.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; Z Y Lin; J H Tsai
Journal:  Liver       Date:  1994-04

10.  Preliminary study of alpha-fetoprotein in nonmalignant liver diseases. A clinico-biochemical evaluation.

Authors:  J Collazos; J Genolla; A Ruibal
Journal:  Int J Biol Markers       Date:  1992 Apr-Jun       Impact factor: 3.248

View more
  20 in total

1.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

Review 2.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China.

Authors:  Yuanyuan Li; Zheng Zhang; Jianfei Shi; Lei Jin; Lifeng Wang; Dongping Xu; Fu-Sheng Wang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 4.  Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.

Authors:  Miki Murata; Katsunori Yoshida; Takashi Yamaguchi; Koichi Matsuzaki
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 5.  Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.

Authors:  Irene Rapti; Stephanos Hadziyannis
Journal:  World J Hepatol       Date:  2015-05-18

6.  Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era.

Authors:  Ken Shirabe; Kazuki Takeishi; Akinobu Taketomi; Hideaki Uchiyama; Hiroto Kayashima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

Review 7.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

8.  Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.

Authors:  Robert D Mair; Antonia Valenzuela; Nghiem B Ha; Walid S Ayoub; Tami Daugherty; Glen A Lutchman; Gabriel Garcia; Aijaz Ahmed; Mindie H Nguyen
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

9.  Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.

Authors:  Takashi Someya; Kenji Ikeda; Satoshi Saitoh; Masahiro Kobayashi; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

10.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.